Zevra Therapeutics, Inc., a rare disease therapeutics company, acquired Acer Therapeutics, Inc. in a transaction valued at approximately $76 million payable upon the achievement of certain regulatory and sales milestones. The acquisition of Acer brings multiple rare disease assets and increases Zevra’s revenue potential with the addition of OLPRUVA, indicated for the treatment of certain urea cycle disorders (UCDs), and expands Zevra’s clinical portfolio with EDSIVO, currently in Phase 3 for ...